Veterinärmedizinische Universität Wien Forschungsinformationssystem VetDoc

Grafischer Link zur Startseite der Vetmeduni Vienna

Moriggl Richard,

** = Publikationen gelistet in SCI/SSCI/Pubmed

2022

Zeitschriftenaufsatz

** Erdogan, F; Qadree, AK; Radu, TB; Orlova, A; de Araujo, ED; Israelian, J; Valent, P; Mustjoki, SM; Herling, M; Moriggl, R; Gunning, PT (2022): Structural and mutational analysis of member-specific STAT functions. Biochim Biophys Acta Gen Subj. 2022; 1866(3):130058

** Woess, K; Macho-Maschler, S; Van Ingen Schenau, DS; Butler, M; Lassnig, C; Valcanover, D; Poelzl, A; Meissl, K; Maurer, B; Brandstoetter, T; Vogl, C; Koren, A; Kubicek, S; Orlova, A; Moriggl, R [and 5 others] (2022): Oncogenic TYK2P760L kinase is effectively targeted by combinatorial TYK2, mTOR and CDK4/6 kinase blockade. Haematologica. 2022;
Open Access Logo [Article in Press]

2021

** Aksoy, O; Pencik, J; Hartenbach, M; Moazzami, AA; Schlederer, M; Balber, T; Varady, A; Philippe, C; Baltzer, PA; Mazumder, B; Whitchurch, JB; Roberts, CJ; Haitel, A; Herac, M; Susani, M [and 22 others] (2021): Thyroid and androgen receptor signaling are antagonized by CRYM in prostate cancer. Int J Cancer. 2021 148 (3) 731-747.

** Beghini, M; Wagner, T; Luca, AC; Metz, M; Kaltenecker, D; Spirk, K; Hackl, MT; Haybaeck, J; Moriggl, R; Kautzky-Willer, A; Scherer, T; Fürnsinn, C (2021): Adipocyte STAT5 deficiency does not affect blood glucose homeostasis in obese mice. PLoS One. 2021; 16(11):e0260501
Open Access Logo

** Bregante, J; Schönbichler, A; Pölöske, D; Degenfeld-Schonburg, L; Monzó Contreras, G; Hadzijusufovic, E; de Araujo, ED; Valent, P; Moriggl, R; Orlova, A (2021): Efficacy and synergy of small molecule inhibitors targeting FLT3-ITD+ acute myeloid Leukemia. Cancers (Basel). 2021; 13(24):6181
Open Access Logo

** Breitenecker, K; Homolya, M; Luca, AC; Lang, V; Trenk, C; Petroczi, G; Mohrherr, J; Horvath, J; Moritsch, S; Haas, L; Kurnaeva, M; Eferl, R; Stoiber, D; Moriggl, R; Bilban, M [and 9 others] (2021): Down-regulation of A20 promotes immune escape of lung adenocarcinomas. Sci Transl Med. 2021; 13(601):eabc3911

** Igelmann, S; Lessard, F; Uchenunu, O; Bouchard, J; Fernandez-Ruiz, A; Rowell, MC; Lopes-Paciencia, S; Papadopoli, D; Fouillen, A; Ponce, KJ; Huot, G; Mignacca, L; Benfdil, M; Kalegari, P; Wahba, HM [and 14 others] (2021): A hydride transfer complex reprograms NAD metabolism and bypasses senescence. Mol Cell. 2021; 81(18):3848-3865.e19

** Kieslinger, M; Swoboda, A; Kramer, N; Freund, P; Pratscher, B; Neubauer, HA; Steinborn, R; Wolfesberger, B; Fuchs-Baumgartinger, A; Moriggl, R; Burgener, IA (2021): A recurrent STAT5BN642H driver mutation in feline alimentary t cell lymphoma. Cancers (Basel). 2021; 13(20):5238
Open Access Logo

** Kim, D; Park, G; Huuhtanen, J; Ghimire, B; Rajala, H; Moriggl, R; Chan, WC; Kankainen, M; Myllymäki, M; Mustjoki, S (2021): STAT3 activation in large granular lymphocyte leukemia is associated with cytokine signaling and DNA hypermethylation. Leukemia. 2021 35 (12) 3430-3443.
Open Access Logo

** Kollmann, S; Grausenburger, R; Klampfl, T; Prchal-Murphy, M; Bastl, K; Pisa, H; Knab, VM; Brandstoetter, T; Doma, E; Sperr, WR; Lagger, S; Farlik, M; Moriggl, R; Valent, P; Halbritter, F [and 4 others] (2021): A STAT5B-CD9 axis determines self-renewal in hematopoietic and leukemic stem cells. Blood. 2021; 138(23):2347-2359

** Poelzl, A; Lassnig, C; Tangermann, S; Hromadová, D; Reichart, U; Gawish, R; Mueller, K; Moriggl, R; Linkermann, A; Glösmann, M; Kenner, L; Mueller, M; Strobl, B (2021): TYK2 licenses non-canonical inflammasome activation during endotoxemia. Cell Death Differ. 2021 28 (2) 748-763.

** Pons, M; Zeyn, Y; Zahn, S; Mahendrarajah, N; Page, BDG; Gunning, PT; Moriggl, R; Brenner, W; Butter, F; Krämer, OH (2021): Oncogenic kinase cascades induce molecular mechanisms that protect leukemic cell models from lethal effects of de novo dntp synthesis inhibition. Cancers (Basel). 2021; 13(14):3464
Open Access Logo

** Schönefeldt, S; Wais, T; Herling, M; Mustjoki, S; Bekiaris, V; Moriggl, R; Neubauer, HA (2021): The diverse roles of γδ t cells in cancer: From rapid immunity to aggressive lymphoma. Cancers (Basel). 2021; 13(24):6212
Open Access Logo

** Surbek, M; Tse, W; Moriggl, R; Han, X (2021): A centric view of JAK/STAT5 in intestinal homeostasis, infection, and inflammation. Cytokine. 2021; 139:155392
Open Access Logo

** Swoboda, A; Soukup, R; Eckel, O; Kinslechner, K; Wingelhofer, B; Schörghofer, D; Sternberg, C; Pham, HTT; Vallianou, M; Horvath, J; Stoiber, D; Kenner, L; Larue, L; Poli, V; Beermann, F [and 12 others] (2021): STAT3 promotes melanoma metastasis by CEBP-induced repression of the MITF pathway. Oncogene. 2021 40 (6) 1091-1105.

** Toutah, K; Nawar, N; Timonen, S; Sorger, H; Raouf, YS; Bukhari, S; von Jan, J; Ianevski, A; Gawel, JM; Olaoye, OO; Geletu, M; Abdeldayem, A; Israelian, J; Radu, TB; Sedighi, A [and 12 others] (2021): Development of HDAC Inhibitors Exhibiting Therapeutic Potential in T-Cell Prolymphocytic Leukemia. J Med Chem. 2021; 64(12):8486-8509
Open Access Logo

** Tripolt, S; Neubauer, HA; Knab, VM; Elmer, DP; Aberger, F; Moriggl, R; Fux, DA (2021): Opioids drive breast cancer metastasis through the δ-opioid receptor and oncogenic STAT3. Neoplasia. 2021; 23(2):270-279
Open Access Logo

** Valent, P; Orfao, A; Kubicek, S; Staber, P; Haferlach, T; Deininger, M; Kollmann, K; Lion, T; Virgolini, I; Winter, G; Hantschel, O; Kenner, L; Zuber, J; Grebien, F; Moriggl, R [and 11 others] (2021): Precision Medicine in Hematology 2021: Definitions, Tools, Perspectives, and Open Questions. Hemasphere. 2021; 5(3):e536
Open Access Logo

** Wiebringhaus, R; Pecoraro, M; Neubauer, HA; Trachtová, K; Trimmel, B; Wieselberg, M; Pencik, J; Egger, G; Krall, C; Moriggl, R; Mann, M; Hantusch, B; Kenner, L (2021): Proteomic analysis identifies ndufs1 and atp5o as novel markers for survival outcome in prostate cancer. Cancers (Basel). 2021; 13(23):6036
Open Access Logo

** Willmann, M; Yuzbasiyan-Gurkan, V; Marconato, L; Dacasto, M; Hadzijusufovic, E; Hermine, O; Sadovnik, I; Gamperl, S; Schneeweiss-Gleixner, M; Gleixner, KV; Böhm, T; Peter, B; Eisenwort, G; Moriggl, R; Li, Z [and 10 others] (2021): Proposed Diagnostic Criteria and Classification of Canine Mast Cell Neoplasms: A Consensus Proposal. Front Vet Sci. 2021; 8:755258
Open Access Logo

Kongressbeitrag in einer Zeitschrift

** Dey, S; Sorger, H; Vieyra-Garcia, P; Araujo, ED; Graf, R; Spiegl, B; Schlederer, M; Graier, T; Perchthaler, I; Fink-Puches, R; Cerroni, L; Surbek, M; Pirker, C; Berger, W; Orlova, A [and 8 others] (2021): STAT5 is a therapeutically targetable vulnerability in leukemic cutaneous T-cell lymphoma. 47th Annual Meeting of the Arbeitsgemeinschaft Dermatologische Forschung (ADF), Online, Germany, March 04‐06, 2021. Exp Dermatol (30), 3 E100-E101.

** Dey, S; Sorger, H; Vieyra-Garcia, PA; de Araujo, ED; Graf, R; Spiegl, B; Lazzeri, I; Herling, M; Neubauer, HA; Merkel, O; Heitzer, E; Gunning, PT; Kenner, L; Moriggl, R; Wolf, P (2021): Chromosome # 17q (17q11.2-17q21.31) gain is a disease marker and therapeutic vulnerability in Sezary Syndrome. 4th Inflammatory Skin Disease Summit, New York, NY, United States, NOV 03-06, 2021. Exp Dermatol (30), S2 14-14.

2020

Zeitschriftenaufsatz

** Abdeldayem, A; Raouf, YS; Constantinescu, SN; Moriggl, R; Gunning, PT (2020): Advances in covalent kinase inhibitors. Chem Soc Rev. 2020; 49(9):2617-2687

** de Araujo, ED; Keserű, GM; Gunning, PT; Moriggl, R (2020): Targeting STAT3 and STAT5 in Cancer. Cancers (Basel). 2020; 12(8):2002
Open Access Logo

** Hadzijusufovic, E; Keller, A; Berger, D; Greiner, G; Wingelhofer, B; Witzeneder, N; Ivanov, D; Pecnard, E; Nivarthi, H; Schur, FKM; Filik, Y; Kornauth, C; Neubauer, HA; Müllauer, L; Tin, G [and 8 others] (2020): STAT5 is Expressed in CD34+/CD38- Stem Cells and Serves as a Potential Molecular Target in Ph-Negative Myeloproliferative Neoplasms. Cancers (Basel). 2020; 12(4):1021
Open Access Logo

** Kadekar, D; Agerholm, R; Rizk, J; Neubauer, HA; Suske, T; Maurer, B; Viñals, MT; Comelli, EM; Taibi, A; Moriggl, R; Bekiaris, V (2020): The neonatal microenvironment programs innate γδ T cells through the transcription factor STAT5. J Clin Invest. 2020; 130(5):2496-2508

** Kaltenecker, D; Spirk, K; Ruge, F; Grebien, F; Herling, M; Rupprecht, A; Kenner, L; Pohl, EE; Mueller, KM; Moriggl, R (2020): STAT5 is required for lipid breakdown and beta-adrenergic responsiveness of brown adipose tissue. Mol Metab. 2020; 40:101026
Open Access Logo

** Maurer, B; Nivarthi, H; Wingelhofer, B; Pham, HTT; Schlederer, M; Suske, T; Grausenburger, R; Schiefer, AI; Prchal-Murphy, M; Chen, D; Winkler, S; Merkel, O; Kornauth, C; Hofbauer, M; Hochgatterer, B [and 23 others] (2020): High activation of STAT5A drives peripheral T-cell lymphoma and leukemia. Haematologica. 2020; 105(2):435-447
Open Access Logo

** Oberbeck, S; Schrader, A; Warner, K; Jungherz, D; Crispatzu, G; von Jan, J; Chmielewski, M; Ianevski, A; Diebner, HH; Mayer, P; Kondo Ados, A; Wahnschaffe, L; Braun, T; Müller, TA; Wagle, P [and 30 others] (2020): Noncanonical effector functions of the T-memory-like T-PLL cell are shaped by cooperative TCL1A and TCR signaling. Blood. 2020; 136(24):2786-2802

** Schmoellerl, J; Barbosa, IAM; Eder, T; Brandstoetter, T; Schmidt, L; Maurer, B; Troester, S; Pham, HTT; Sagarajit, M; Ebner, J; Manhart, G; Aslan, E; Terlecki-Zaniewicz, S; Van der Veen, C; Hoermann, G [and 12 others] (2020): CDK6 is an essential direct target of NUP98-fusion proteins in acute myeloid leukemia. Blood. 2020; 136(4):387-400

** Unterleuthner, D; Neuhold, P; Schwarz, K; Janker, L; Neuditschko, B; Nivarthi, H; Crncec, I; Kramer, N; Unger, C; Hengstschläger, M; Eferl, R; Moriggl, R; Sommergruber, W; Gerner, C; Dolznig, H (2020): Cancer-associated fibroblast-derived WNT2 increases tumor angiogenesis in colon cancer. Angiogenesis. 2020; 23(2):159-177
Open Access Logo

Kongressbeitrag in einer Zeitschrift

** Neubauer, HA; Suske, T; Schonefeldt, S; Tangermann, S; Boersma, A; Rulicke, T; Bekiaris, V; Kenner, L; Moriggl, R (2020): The gain-of-function STAT5B(N642H) mutation as a driver of mature T cell leukemia/lymphoma. AACR Annual Meeting, Philadelphia, PA, United States, JUN 22-24, 2020. Cancer Res (80), 16 2752.

** Orlova, A; Kosack, L; Popa, AM; Viczenczova, C; Lercher, A; de Araujo, ED; Gunning, P; Moriggl, R; Bergthaler, A (2020): Restoration of tumor immunosurveillance in tasmanian devil facial tumor disease. AACR Annual Meeting, Philadelphia, PA, United States, JUN 22-24, 2020. Cancer Res (80), 16 5636.

** Park, JS; Tin, G; de Araujo, ED; Orlova, A; Sorger, H; Grebien, F; Heyes, E; Geletu, M; Villalonga, R; Sampedro, A; Sedighi, A; Herling, M; Mustjoki, S; Eram, MS; Ahmar, S [and 7 others] (2020): A potent and selective small molecule degrader of STAT5 for the treatment of hematological malignancies. AACR Annual Meeting, Philadelphia, PA, United States, JUN 22-24, 2020. Cancer Res (80), 16 LB-108.

2019

Zeitschriftenaufsatz

** Aigner, P; Mizutani, T; Horvath, J; Eder, T; Heber, S; Lind, K; Just, V; Moll, HP; Yeroslaviz, A; Fischer, MJM; Kenner, L; Győrffy, B; Sill, H; Grebien, F; Moriggl, R [and 2 others] (2019): STAT3β is a tumor suppressor in acute myeloid leukemia. Blood Adv. 2019; 3(13):1989-2002
Open Access Logo

** Boutillon, F; Pigat, N; Sala, LS; Reyes-Gomez, E; Moriggl, R; Guidotti, JE; Goffin, V (2019): STAT5a/b Deficiency Delays, but does not Prevent, Prolactin-Driven Prostate Tumorigenesis in Mice. Cancers (Basel). 2019; 11(7):929
Open Access Logo

** de Araujo, ED; Erdogan, F; Neubauer, HA; Meneksedag-Erol, D; Manaswiyoungkul, P; Eram, MS; Seo, HS; Qadree, AK; Israelian, J; Orlova, A; Suske, T; Pham, HTT; Boersma, A; Tangermann, S; Kenner, L [and 9 others] (2019): Structural and functional consequences of the STAT5B Nat Commun. 2019; 10(1):2517
Open Access Logo

** de Araujo, ED; Orlova, A; Neubauer, HA; Bajusz, D; Seo, HS; Dhe-Paganon, S; Keserű, GM; Moriggl, R; Gunning, PT (2019): Structural Implications of STAT3 and STAT5 SH2 Domain Mutations. Cancers (Basel). 2019; 11(11):1757
Open Access Logo

** Duvigneau, JC; Luís, A; Gorman, AM; Samali, A; Kaltenecker, D; Moriggl, R; Kozlov, AV (2019): Crosstalk between inflammatory mediators and endoplasmic reticulum stress in liver diseases. Cytokine. 2019; 124:154577

** Golob-Schwarzl, N; Bettermann, K; Mehta, AK; Kessler, SM; Unterluggauer, J; Krassnig, S; Kojima, K; Chen, X; Hoshida, Y; Bardeesy, NM; Müller, H; Svendova, V; Schimek, MG; Diwoky, C; Lipfert, A [and 13 others] (2019): High Keratin 8/18 Ratio Predicts Aggressive Hepatocellular Cancer Phenotype. Transl Oncol. 2019; 12(2):256-268
Open Access Logo

** Ilangumaran, S; Moriggl, R; Kalvakolanu, DV (2019): Editorial: Cytokines in liver diseases. Cytokine. 2019; 124:154608

** Kaltenecker, D; Themanns, M; Mueller, KM; Spirk, K; Golob-Schwarzl, N; Friedbichler, K; Kenner, L; Haybaeck, J; Moriggl, R (2019): STAT5 deficiency in hepatocytes reduces diethylnitrosamine-induced liver tumorigenesis in mice. Cytokine. 2019; 124:154573
Open Access Logo

** Kaltenecker, D; Themanns, M; Mueller, KM; Spirk, K; Suske, T; Merkel, O; Kenner, L; Luís, A; Kozlov, A; Haybaeck, J; Müller, M; Han, X; Moriggl, R (2019): Hepatic growth hormone - JAK2 - STAT5 signalling: Metabolic function, non-alcoholic fatty liver disease and hepatocellular carcinoma progression. Cytokine. 2019; 124:154569
Open Access Logo

** Klein, K; Witalisz-Siepracka, A; Maurer, B; Prinz, D; Heller, G; Leidenfrost, N; Prchal-Murphy, M; Suske, T; Moriggl, R; Sexl, V (2019): STAT5BN642H drives transformation of NKT cells: a novel mouse model for CD56+ T-LGL leukemia. Leukemia. 2019; 33(9):2336-2340
Open Access Logo

** Kleinegger, F; Hofer, E; Wodlej, C; Golob-Schwarzl, N; Birkl-Toeglhofer, AM; Stallinger, A; Petzold, J; Orlova, A; Krassnig, S; Reihs, R; Niedrist, T; Mangge, H; Park, YN; Thalhammer, M; Aigelsreiter, A [and 7 others] (2019): Pharmacologic IL-6Rα inhibition in cholangiocarcinoma promotes cancer cell growth and survival. Biochim Biophys Acta Mol Basis Dis. 2019; 1865(2):308-321
Open Access Logo

** Kosack, L; Wingelhofer, B; Popa, A; Orlova, A; Agerer, B; Vilagos, B; Majek, P; Parapatics, K; Lercher, A; Ringler, A; Klughammer, J; Smyth, M; Khamina, K; Baazim, H; de Araujo, ED [and 13 others] (2019): The ERBB-STAT3 Axis Drives Tasmanian Devil Facial Tumor Disease. Cancer Cell. 2019; 35(1):125-139.e9
Open Access Logo

** Lercher, A; Bhattacharya, A; Popa, AM; Caldera, M; Schlapansky, MF; Baazim, H; Agerer, B; Gürtl, B; Kosack, L; Májek, P; Brunner, JS; Vitko, D; Pinter, T; Genger, JW; Orlova, A [and 13 others] (2019): Type I Interferon Signaling Disrupts the Hepatic Urea Cycle and Alters Systemic Metabolism to Suppress T Cell Function. Immunity. 2019; 51(6):1074-1087.e9
Open Access Logo

** Liu, R; Moriggl, R; Zhang, D; Li, H; Karns, R; Ruan, HB; Niu, H; Mayhew, C; Watson, C; Bangar, H; Cha, SW; Haslam, D; Zhang, T; Gilbert, S; Li, N [and 4 others] (2019): Constitutive STAT5 activation regulates Paneth and Paneth-like cells to control Clostridium difficile colitis. Life Sci Alliance. 2019; 2(2):
Open Access Logo

** Mohrherr, J; Haber, M; Breitenecker, K; Aigner, P; Moritsch, S; Voronin, V; Eferl, R; Moriggl, R; Stoiber, D; Győrffy, B; Brcic, L; László, V; Döme, B; Moldvay, J; Dezső, K [and 4 others] (2019): JAK-STAT inhibition impairs K-RAS-driven lung adenocarcinoma progression. Int J Cancer. 2019; 145(12):3376-3388
Open Access Logo

** Muller, A; Gasch, J; Albring, KF; Aberger, F; Nivarthi, H; Khemeri, M; Moriggl, R; Friedrich, KH (2019): Interplay of transcription factors STAT3, STAT1 and AP-1 mediates activity of the matrix metallo-proteinase-1 promoter in colorectal carcinoma cells. Neoplasma. 2019; 66(3):357-366

** Orlova, A; Neubauer, HA; Moriggl, R (2019): The stromal microenvironment provides an escape route from FLT3 inhibitors through the GAS6-AXL-STAT5 axis. Haematologica. 2019; 104(10):1907-1909
Open Access Logo

** Orlova, A; Wagner, C; de Araujo, ED; Bajusz, D; Neubauer, HA; Herling, M; Gunning, PT; Keserű, GM; Moriggl, R (2019): Direct Targeting Options for STAT3 and STAT5 in Cancer. Cancers (Basel). 2019; 11(12):1930
Open Access Logo

** Prutsch, N; Gurnhofer, E; Suske, T; Liang, HC; Schlederer, M; Roos, S; Wu, LC; Simonitsch-Klupp, I; Alvarez-Hernandez, A; Kornauth, C; Leone, DA; Svinka, J; Eferl, R; Limberger, T; Aufinger, A [and 18 others] (2019): Dependency on the TYK2/STAT1/MCL1 axis in anaplastic large cell lymphoma. Leukemia. 2019; 33(3):696-709

** Rauth, M; Freund, P; Orlova, A; Grünert, S; Tasic, N; Han, X; Ruan, HB; Neubauer, HA; Moriggl, R (2019): Cell Metabolism Control Through O-GlcNAcylation of STAT5: A Full or Empty Fuel Tank Makes a Big Difference for Cancer Cell Growth and Survival. Int J Mol Sci. 2019; 20(5): 1028.
Open Access Logo

Kongressbeitrag in einer Zeitschrift

** Aksoy, O; Pencik, J; Varady, A; Moazzami, A; Schlederer, M; Balber, T; Susani, M; Hassler, M; Greiner, G; Javaheri, T; Turner, S; Egger, G; Moriggl, R; Culig, Z; Merkel, O; Kenner, L (2019): Cooperative Androgen and Thyroid Hormone Signaling Drives Prostate Cancer. 52nd Conference of the European-Society-of-Human-Genetics (ESHG), Gothenburg, Sweden, JUN 15-18, 2019. Eur J Hum Genet (27), S2 1595-1596.

2018

Zeitschriftenaufsatz

** Abu Eid, S; Hackl, MT; Kaplanian, M; Winter, MP; Kaltenecker, D; Moriggl, R; Luger, A; Scherer, T; Fürnsinn, C (2018): Life Under Hypoxia Lowers Blood Glucose Independently of Effects on Appetite and Body Weight in Mice. Front Endocrinol (Lausanne). 2018; 9:490
Open Access Logo

** Keller, A; Wingelhofer, B; Peter, B; Bauer, K; Berger, D; Gamperl, S; Reifinger, M; Cerny-Reiterer, S; Moriggl, R; Willmann, M; Valent, P; Hadzijusufovic, E (2018): The JAK2/STAT5 signaling pathway as a potential therapeutic target in canine mastocytoma. Vet Comp Oncol. 2018; 16(1):55-68
Open Access Logo

** Kinslechner, K; Schörghofer, D; Schütz, B; Vallianou, M; Wingelhofer, B; Mikulits, W; Röhrl, C; Hengstschläger, M; Moriggl, R; Stangl, H; Mikula, M (2018): Malignant Phenotypes in Metastatic Melanoma are Governed by SR-BI and its Association with Glycosylation and STAT5 Activation. Mol Cancer Res. 2018; 16(1):135-146
Open Access Logo

** Moll, HP; Pranz, K; Musteanu, M; Grabner, B; Hruschka, N; Mohrherr, J; Aigner, P; Stiedl, P; Brcic, L; Laszlo, V; Schramek, D; Moriggl, R; Eferl, R; Moldvay, J; Dezso, K [and 10 others] (2018): Afatinib restrains K-RAS-driven lung tumorigenesis. Sci Transl Med. 2018; 10(446):

** Orlova, A; Wingelhofer, B; Neubauer, HA; Maurer, B; Berger-Becvar, A; Keserű, GM; Gunning, PT; Valent, P; Moriggl, R (2018): Emerging therapeutic targets in myeloproliferative neoplasms and peripheral T-cell leukemia and lymphomas. Expert Opin Ther Targets. 2018; 22(1):45-57
Open Access Logo

** Peter, B; Bibi, S; Eisenwort, G; Wingelhofer, B; Berger, D; Stefanzl, G; Blatt, K; Herrmann, H; Hadzijusufovic, E; Hoermann, G; Hoffmann, T; Schwaab, J; Jawhar, M; Willmann, M; Sperr, WR [and 7 others] (2018): Drug-induced inhibition of phosphorylation of STAT5 overrides drug resistance in neoplastic mast cells. Leukemia. 2018; 32(4):1016-1022
Open Access Logo

** Pham, HTT; Hengstschläger, M; Moriggl, R (2018): A haunted beast: Targeting STAT5B Mol Cell Oncol. 2018; 5(3):e1435181
Open Access Logo

** Pham, HTT; Maurer, B; Prchal-Murphy, M; Grausenburger, R; Grundschober, E; Javaheri, T; Nivarthi, H; Boersma, A; Kolbe, T; Elabd, M; Halbritter, F; Pencik, J; Kazemi, Z; Grebien, F; Hengstschläger, M [and 9 others] (2018): STAT5BN642H is a driver mutation for T cell neoplasia. J Clin Invest. 2018; 128(1):387-401
Open Access Logo

** Schrader, A; Crispatzu, G; Oberbeck, S; Mayer, P; Pützer, S; von Jan, J; Vasyutina, E; Warner, K; Weit, N; Pflug, N; Braun, T; Andersson, EI; Yadav, B; Riabinska, A; Maurer, B [and 21 others] (2018): Actionable perturbations of damage responses by TCL1/ATM and epigenetic lesions form the basis of T-PLL. Nat Commun. 2018; 9(1):697
Open Access Logo

** Seidi, K; Jahanban-Esfahlan, R; Monhemi, H; Zare, P; Minofar, B; Daei Farshchi Adli, A; Farajzadeh, D; Behzadi, R; Mesgari Abbasi, M; Neubauer, HA; Moriggl, R; Zarghami, N; Javaheri, T (2018): NGR (Asn-Gly-Arg)-targeted delivery of coagulase to tumor vasculature arrests cancer cell growth. Oncogene. 2018; 37(29):3967-3980
Open Access Logo

** Seidi, K; Neubauer, HA; Moriggl, R; Jahanban-Esfahlan, R; Javaheri, T (2018): Tumor target amplification: Implications for nano drug delivery systems. J Control Release. 2018; 275:142-161

** Sternberg, C; Gruber, W; Eberl, M; Tesanovic, S; Stadler, M; Elmer, DP; Schlederer, M; Grund, S; Roos, S; Wolff, F; Kaur, S; Mangelberger, D; Lehrach, H; Hache, H; Wierling, C [and 9 others] (2018): Synergistic cross-talk of hedgehog and interleukin-6 signaling drives growth of basal cell carcinoma. Int J Cancer. 2018; 143(11):2943-2954
Open Access Logo

** Valent, P; Büsche, G; Theurl, I; Uras, IZ; Germing, U; Stauder, R; Sotlar, K; Füreder, W; Bettelheim, P; Pfeilstöcker, M; Oberbauer, R; Sperr, WR; Geissler, K; Schwaller, J; Moriggl, R [and 4 others] (2018): Normal and pathological erythropoiesis in adults: from gene regulation to targeted treatment concepts. Haematologica. 2018; 103(10):1593-1603
Open Access Logo

** Wingelhofer, B; Maurer, B; Heyes, EC; Cumaraswamy, AA; Berger-Becvar, A; de Araujo, ED; Orlova, A; Freund, P; Ruge, F; Park, J; Tin, G; Ahmar, S; Lardeau, CH; Sadovnik, I; Bajusz, D [and 6 others] (2018): Pharmacologic inhibition of STAT5 in acute myeloid leukemia. Leukemia. 2018; 32(5):1135-1146
Open Access Logo

** Wingelhofer, B; Neubauer, HA; Valent, P; Han, X; Constantinescu, SN; Gunning, PT; Müller, M; Moriggl, R (2018): Implications of STAT3 and STAT5 signaling on gene regulation and chromatin remodeling in hematopoietic cancer. Leukemia. 2018; 32(8):1713-1726
Open Access Logo

** Zboray, K; Mohrherr, J; Stiedl, P; Pranz, K; Wandruszka, L; Grabner, B; Eferl, R; Moriggl, R; Stoiber, D; Sakamoto, K; Wagner, KU; Popper, H; Casanova, E; Moll, HP (2018): AKT3 drives adenoid cystic carcinoma development in salivary glands. Cancer Med. 2018; 7(2):445-453
Open Access Logo

2017

** Boidol, B; Kornauth, C; van der Kouwe, E; Prutsch, N; Kazianka, L; Gültekin, S; Hoermann, G; Mayerhoefer, ME; Hopfinger, G; Hauswirth, A; Panny, M; Aretin, MB; Hilgarth, B; Sperr, WR; Valent, P [and 7 others] (2017): First-in-human response of BCL-2 inhibitor venetoclax in T-cell prolymphocytic leukemia. Blood. 2017; 130(23):2499-2503

** Bourgeais, J; Ishac, N; Medrzycki, M; Brachet-Botineau, M; Desbourdes, L; Gouilleux-Gruart, V; Pecnard, E; Rouleux-Bonnin, F; Gyan, E; Domenech, J; Mazurier, F; Moriggl, R; Bunting, KD; Herault, O; Gouilleux, F (2017): Oncogenic STAT5 signaling promotes oxidative stress in chronic myeloid leukemia cells by repressing antioxidant defenses. Oncotarget. 2017; 8(26):41876-41889
Open Access Logo

** Edlinger, L; Berger-Becvar, A; Menzl, I; Hoermann, G; Greiner, G; Grundschober, E; Bago-Horvath, Z; Al-Zoughbi, W; Hoefler, G; Brostjan, C; Gille, L; Moriggl, R; Spittler, A; Sexl, V; Hoelbl-Kovacic, A (2017): Expansion of BCR/ABL1(+) cells requires PAK2 but not PAK1. Br J Haematol. 2017; 179(2):229-241
Open Access Logo

** Eigner, K; Filik, Y; Mark, F; Schütz, B; Klambauer, G; Moriggl, R; Hengstschläger, M; Stangl, H; Mikula, M; Röhrl, C (2017): The unfolded protein response impacts melanoma progression by enhancing FGF expression and can be antagonized by a chemical chaperone. Sci Rep. 2017; 7(1):17498
Open Access Logo

** Eiring, AM; Page, BDG; Kraft, IL; Mason, CC; Vellore, NA; Resetca, D; Zabriskie, MS; Zhang, TY; Khorashad, JS; Engar, AJ; Reynolds, KR; Anderson, DJ; Senina, A; Pomicter, AD; Arpin, CC [and 11 others] (2017): Combined STAT3 and BCR-ABL1 inhibition induces synthetic lethality in therapy-resistant chronic myeloid leukemia. Leukemia 31(5): 1253-1254.

** Fragiadaki, M; Lannoy, M; Themanns, M; Maurer, B; Leonhard, WN; Peters, DJ; Moriggl, R; Ong, AC (2017): STAT5 drives abnormal proliferation in autosomal dominant polycystic kidney disease. Kidney Int. 2017; 91(3):575-586

** Freund, P; Kerenyi, MA; Hager, M; Wagner, T; Wingelhofer, B; Pham, HTT; Elabd, M; Han, X; Valent, P; Gouilleux, F; Sexl, V; Krämer, OH; Groner, B; Moriggl, R (2017): O-GlcNAcylation of STAT5 controls tyrosine phosphorylation and oncogenic transcription in STAT5-dependent malignancies. Leukemia. 2017; 31(10):2132-2142
Open Access Logo

** Friedrich, K; Dolznig, H; Han, X; Moriggl, R (2017): Steering of carcinoma progression by the YIN/YANG interaction of STAT1/STAT3. Biosci Trends. 2017; 11(1):1-8

** Ghanem, S; Friedbichler, K; Boudot, C; Bourgeais, J; Gouilleux-Gruart, V; Régnier, A; Herault, O; Moriggl, R; Gouilleux, F (2017): STAT5A/5B-specific expansion and transformation of hematopoietic stem cells. Blood Cancer J. 2017; 7(1):e514
Open Access Logo

** Gleixner, KV; Schneeweiss, M; Eisenwort, G; Berger, D; Herrmann, H; Blatt, K; Greiner, G; Byrgazov, K; Hoermann, G; Konopleva, M; Waliul, I; Cumaraswamy, AA; Gunning, PT; Maeda, H; Moriggl, R [and 4 others] (2017): Combined targeting of STAT3 and STAT5: a novel approach to overcome drug resistance in chronic myeloid leukemia. Haematologica. 2017; 102(9):1519-1529
Open Access Logo

** Kaltenecker, D; Mueller, KM; Benedikt, P; Feiler, U; Themanns, M; Schlederer, M; Kenner, L; Schweiger, M; Haemmerle, G; Moriggl, R (2017): Adipocyte STAT5 deficiency promotes adiposity and impairs lipid mobilisation in mice. Diabetologia (60), 2 296-305.
Open Access Logo

** Kramer, N; Schmöllerl, J; Unger, C; Nivarthi, H; Rudisch, A; Unterleuthner, D; Scherzer, M; Riedl, A; Artaker, M; Crncec, I; Lenhardt, D; Schwarz, T; Prieler, B; Han, X; Hengstschläger, M [and 5 others] (2017): Autocrine WNT2 signaling in fibroblasts promotes colorectal cancer progression. Oncogene. 2017; 36(39):5460-5472

** Merkel, O; Taylor, N; Prutsch, N; Staber, PB; Moriggl, R; Turner, SD; Kenner, L (2017): When the guardian sleeps: Reactivation of the p53 pathway in cancer. Mutat Res. 2017; 773:1-13

** Minas, TZ; Surdez, D; Javaheri, T; Tanaka, M; Howarth, M; Kang, HJ; Han, J; Han, ZY; Sax, B; Kream, BE; Hong, SH; Çelik, H; Tirode, F; Tuckermann, J; Toretsky, JA [and 8 others] (2017): Combined experience of six independent laboratories attempting to create an Ewing sarcoma mouse model. Oncotarget. 2017; 8(21):34141-34163
Open Access Logo

** Mueller, KM; Hartmann, K; Kaltenecker, D; Vettorazzi, S; Bauer, M; Mauser, L; Amann, S; Jall, S; Fischer, K; Esterbauer, H; Müller, TD; Tschöp, MH; Magnes, C; Haybaeck, J; Scherer, T [and 3 others] (2017): Adipocyte Glucocorticoid Receptor Deficiency Attenuates Aging- and HFD-Induced Obesity and Impairs the Feeding-Fasting Transition. Diabetes. 2017; 66(2):272-286

** Rosner, M; Pham, HTT; Moriggl, R; Hengstschläger, M (2017): Human stem cells alter the invasive properties of somatic cells via paracrine activation of mTORC1. Nat Commun. 2017; 8(1):595
Open Access Logo

** Sackmann Sala, L; Boutillon, F; Menara, G; De Goyon-Pélard, A; Leprévost, M; Codzamanian, J; Lister, N; Pencik, J; Clark, A; Cagnard, N; Bole-Feysot, C; Moriggl, R; Risbridger, GP; Taylor, RA; Kenner, L [and 2 others] (2017): A rare castration-resistant progenitor cell population is highly enriched in Pten-null prostate tumours. J Pathol. 2017; 243(1):51-64

Kongressbeitrag in einer Zeitschrift

Greiner, G; Witzeneder, N; Berger, A; Schmetterer, K; Eisenworth, G; Schiefer, A; Roos, S; Popow-kraupp, T; Müllauer, L; Zuber, J; Sexl, V; Kenner, L; Sperr, WR; Mayerhofer, M; Valent, P; Hoermann, G (2017): ccl-2 Is A Kit D816v-dependent Modulator Of The Bone Marrow Microenvironment In Systemic Mastocytosis: Cod: T210. Euromedlab 2017 Athen, Athen, Greece, June 11-15, 2017. Clinical Chemistry and Laboratory Medicine (55) 709-709.

Gruber, ES; Birner, P; Merkel, O; Bergmann, M; Schoppmann, SF; Park, J; Moriggl, R; Tse, W; Kenner, L (2017): The coactivator oncogene AF1Q associates with STAT3 activation downstream of MET action in gastro-esophageal cancer patients. AACR, Washington DC, United States, April 1-5, 2017. Cancer Research (70), 13 4463-4463.

Prutsch, N; Sanda, T; Wu, L; Turner, S; Jaeger, U; Staber, P; Steinberger, P; Moriggl, R; Mueller, M; Kenner, L; Merkel, O (2017): The TYK2-STAT1 pathway in aggressive T-Cell Lymphoma: A new therapeutic intervention site? ÖGBMT, Innsbruck, Austria, Sep 25-27, 2017. Oncology Research And Treatment (40) 239-239.

2016

Zeitschriftenaufsatz

** Bauer, E; Schlederer, M; Scheicher, R; Horvath, J; Aigner, P; Schiefer, AI; Kain, R; Regele, H; Hoermann, G; Steiner, G; Kenner, L; Sexl, V; Villunger, A; Moriggl, R; Stoiber, D (2016): Cooperation of ETV6/RUNX1 and BCL2 enhances immunoglobulin production and accelerates glomerulonephritis in transgenic mice. Oncotarget. 2016; 7(11):12191-12205
Open Access Logo

** Birner, P; Heider, S; Petzelbauer, P; Wolf, P; Kornauth, C; Kuroll, M; Merkel, O; Steiner, G; Kishimoto, T; Rose-John, S; Soleiman, A; Moriggl, R; Kenner, L (2016): Interleukin-6 receptor alpha blockade improves skin lesions in a murine model of systemic lupus erythematosus. Exp Dermatol. 2016; 25(4):305-310
Open Access Logo

** Gotthardt, D; Putz, EM; Grundschober, E; Prchal-Murphy, M; Straka, E; Kudweis, P; Heller, G; Bago-Horvath, Z; Witalisz-Siepracka, A; Cumaraswamy, AA; Gunning, PT; Strobl, B; Müller, M; Moriggl, R; Stockmann, C; Sexl, V (2016): STAT5 Is a Key Regulator in NK Cells and Acts as a Molecular Switch from Tumor Surveillance to Tumor Promotion. Cancer Discov. 2016; 6(4):414-429

** Javaheri, T; Kazemi, Z; Pencik, J; Pham, HT; Kauer, M; Noorizadeh, R; Sax, B; Nivarthi, H; Schlederer, M; Maurer, B; Hofbauer, M; Aryee, DN; Wiedner, M; Tomazou, EM; Logan, M [and 10 others] (2016): Increased survival and cell cycle progression pathways are required for EWS/FLI1-induced malignant transformation. Cell Death Dis. 2016; 7(10):e2419
Open Access Logo

** Jayavelu, AK; Müller, JP; Bauer, R; Böhmer, SA; Lässig, J; Cerny-Reiterer, S; Sperr, WR; Valent, P; Maurer, B; Moriggl, R; Schröder, K; Shah, AM; Fischer, M; Scholl, S; Barth, J [and 7 others] (2016): NOX4-driven ROS formation mediates PTP inactivation and cell transformation in FLT3ITD-positive AML cells. Leukemia. 2016; 30(2):473-483

** Kollmann, K; Heller, G; Schneckenleithner, C; Warsch, W; Scheicher, R; Ott, RG; Schäfer, M; Fajmann, S; Schlederer, M; Schiefer, AI; Reichart, U; Mayerhofer, M; Hoeller, C; Zöchbauer-Müller, S; Kerjaschki, D [and 9 others] (2016): A Kinase-Independent Function of CDK6 Links the Cell Cycle to Tumor Angiogenesis. Cancer Cell 30(2): 359-360.

** Kovar, H; Amatruda, J; Brunet, E; Burdach, S; Cidre-Aranaz, F; de Alava, E; Dirksen, U; van der Ent, W; Grohar, P; Grünewald, TG; Helman, L; Houghton, P; Iljin, K; Korsching, E; Ladanyi, M [and 31 others] (2016): The second European interdisciplinary Ewing sarcoma research summit - A joint effort to deconstructing the multiple layers of a complex disease. Oncotarget. 2016; 7(8):8613-8624
Open Access Logo

** Nivarthi, H; Gordziel, C; Themanns, M; Kramer, N; Eberl, M; Rabe, B; Schlederer, M; Rose-John, S; Knösel, T; Kenner, L; Freund, P; Aberger, F; Han, X; Kralovics, R; Dolznig, H [and 3 others] (2016): The ratio of STAT1 to STAT3 expression is a determinant of colorectal cancer growth. Oncotarget. 2016; 7(32):51096-51106
Open Access Logo

** Park, J; Kim, S; Joh, J; Remick, SC; Miller, DM; Yan, J; Kanaan, Z; Chao, JH; Krem, MM; Basu, SK; Hagiwara, S; Kenner, L; Moriggl, R; Bunting, KD; Tse, W (2016): MLLT11/AF1q boosts oncogenic STAT3 activity through Src-PDGFR tyrosine kinase signaling. Oncotarget. 2016; 7(28):43960-43973
Open Access Logo

** Pencik, J; Pham, HT; Schmoellerl, J; Javaheri, T; Schlederer, M; Culig, Z; Merkel, O; Moriggl, R; Grebien, F; Kenner, L (2016): JAK-STAT signaling in cancer: From cytokines to non-coding genome. Cytokine. 2016; 87:26-36
Open Access Logo

** Themanns, M; Mueller, KM; Kessler, SM; Golob-Schwarzl, N; Mohr, T; Kaltenecker, D; Bourgeais, J; Paier-Pourani, J; Friedbichler, K; Schneller, D; Schlederer, M; Zebedin-Brandl, E; Terracciano, LM; Han, X; Kenner, L [and 7 others] (2016): Hepatic Deletion of Janus Kinase 2 Counteracts Oxidative Stress in Mice. Sci Rep. 2016; 6:34719
Open Access Logo

Kongressbeitrag in einer Zeitschrift

** Gleixner, KV; Schneeweiss, MA; Herrmann, H; Blatt, K; Berger, D; Eisenwort, G; Greiner, G; Byrgazov, K; Hoermann, G; Konopleva, M; Waliul, I; Gunning, PT; Maeda, H; Moriggl, R; Deininger, MW [and 3 others] (2016): Combined Targeting of STAT3 and STAT5: A Novel Approach to Overcome Drug Resistance in Ph+ Cml. 58th Annual Meeting and Exposition of the American-Society-of-Hematology (ASH), San Diego, CA, United States, DEC 03-06, 2016. Blood (128), 22

** Kinslechner, K; Schörghofer, D; Schütz, B; Vallianou, M; Röhrl, C; Hengstschläger, M; Moriggl, R; Stangl, H; Mikula, M (2016): The HDL receptor controls the metabolic phenotype of human metastatic melanoma cells. 16th World Congress on Cancers of the Skin, Vienna, AUSTRIA, Austria, AUG 31 - SEP 3, 2016. Melanoma Res (26) E17-E17.

** Maurer, B; Nivarthi, H; Prchal-Murphy, M; Wingelhofer, B; Chen, D; Winkler, S; Schlederer, M; Pham, HTT; Kenner, L; Sexl, V; Kolbe, T; Kralovics, R; Muller, M; Rülicke, T; Moriggl, R (2016): Activated Stat5 Drives Peripheral T Cell Lymphomas. 21st Congress of the European-Hematology-Association, Copenhagen, DENMARK, Denmark, JUN 09-12, 2016. Haematologica (101), S1 567-567.

** Prutsch, N; Sanda, T; Wu, L; Turner, S; Jaeger, U; Staber, P; Steinberger, P; Moriggl, R; Mueller, M; Kenner, L; Merkel, O (2016): The TYK2-STAT1 pathway in aggressive T-Cell Lymphoma: A new therapeutic intervention site. Jahrestagung der ­Deutschen, Österreichischen und ­Schweizerischen ­Gesellschaften für Hämatologie und ­Medizinische Onkologie, Leipzig, Germany, Germany, OCT 14–18, 2016. Oncol Res Treat (39), S3 239-239.

** Wingelhofer, B; Heyes, EC; Maurer, B; Lewis, AM; Cumaraswamy, AA; Sadovnik, I; Berger-Becvar, A; Sexl, V; Valent, P; Kubicek, S; Gunning, PT; Moriggl, R (2016): Identification of a novel STAT5 inhibitor to interfere with the oncogenic activities of STAT5 in AML. 21st Congress of the European-Hematology-Association, Copenhagen, DENMARK, Denmark, JUN 09-12, 2016. Haematologica (101), S1 211-211.

Publizierter (zitierfähiger) Beitrag für wissenschaftliche Veranstaltung in Proceedings (A2)

Prutsch, N; Sanda, T; Turner, S; Wu, L; Müller, M; Jäger, U; Staber, P; Simonitsch-Klupp, I; Alvarez-Hernandez, A; Gurnhofer, E; Suske, T; Grebien, F; Stoiber, D; Schlederer, M; Moriggl, R [and 2 others] (2016): The TYK2-STAT1 pathway in aggressive T-Cell Lymphoma: A novel therapeutic intervention site? -Jahrestagung Österreichische Gesellschaft für Hämatologie und Onkologie (OeGHO); März 17-19, 2016; Vienna, Austria.

2015

Zeitschriftenaufsatz

** Eiring, AM; Page, BD; Kraft, IL; Mason, CC; Vellore, NA; Resetca, D; Zabriskie, MS; Zhang, TY; Khorashad, JS; Engar, AJ; Reynolds, KR; Anderson, DJ; Senina, A; Pomicter, AD; Arpin, CC [and 11 others] (2015): Combined STAT3 and BCR-ABL1 inhibition induces synthetic lethality in therapy-resistant chronic myeloid leukemia. Leukemia. 2015; 29(3):586-597

** Gilbert, S; Nivarthi, H; Mayhew, CN; Lo, YH; Noah, TK; Vallance, J; Rülicke, T; Müller, M; Jegga, AG; Tang, W; Zhang, D; Helmrath, M; Shroyer, N; Moriggl, R; Han, X (2015): Activated STAT5 confers resistance to intestinal injury by increasing intestinal stem cell proliferation and regeneration. Stem Cell Reports. 2015; 4(2):209-225
Open Access Logo

** Girardot, M; Pecquet, C; Chachoua, I; Van Hees, J; Guibert, S; Ferrant, A; Knoops, L; Baxter, EJ; Beer, PA; Giraudier, S; Moriggl, R; Vainchenker, W; Green, AR; Constantinescu, SN (2015): Persistent STAT5 activation in myeloid neoplasms recruits p53 into gene regulation. Oncogene. 2015; 34(10):1323-1332

** Grabner, B; Schramek, D; Mueller, KM; Moll, HP; Svinka, J; Hoffmann, T; Bauer, E; Blaas, L; Hruschka, N; Zboray, K; Stiedl, P; Nivarthi, H; Bogner, E; Gruber, W; Mohr, T [and 14 others] (2015): Disruption of STAT3 signalling promotes KRAS-induced lung tumorigenesis. Nat Commun. 2015; 6:6285
Open Access Logo

** Lin, Q; Chauvistré, H; Costa, IG; Gusmao, EG; Mitzka, S; Hänzelmann, S; Baying, B; Klisch, T; Moriggl, R; Hennuy, B; Smeets, H; Hoffmann, K; Benes, V; Seré, K; Zenke, M (2015): Epigenetic program and transcription factor circuitry of dendritic cell development. Nucleic Acids Res. 2015; 43(20):9680-9693
Open Access Logo

** Merkel, O; Hamacher, F; Griessl, R; Grabner, L; Schiefer, AI; Prutsch, N; Baer, C; Egger, G; Schlederer, M; Krenn, PW; Hartmann, TN; Simonitsch-Klupp, I; Plass, C; Staber, PB; Moriggl, R [and 3 others] (2015): Oncogenic role of miR-155 in anaplastic large cell lymphoma lacking the t(2;5) translocation. J Pathol. 2015; 236(4):445-456
Open Access Logo

** Minas, TZ; Han, J; Javaheri, T; Hong, SH; Schlederer, M; Saygideğer-Kont, Y; Çelik, H; Mueller, KM; Temel, I; Özdemirli, M; Kovar, H; Erkizan, HV; Toretsky, J; Kenner, L; Moriggl, R; Üren, A (2015): YK-4-279 effectively antagonizes EWS-FLI1 induced leukemia in a transgenic mouse model. Oncotarget. 2015; 6(35):37678-37694
Open Access Logo

** Nivarthi, H; Prchal-Murphy, M; Swoboda, A; Hager, M; Schlederer, M; Kenner, L; Tuckermann, J; Sexl, V; Moriggl, R; Ermakova, O (2015): Stat5 gene dosage in T cells modulates CD8+ T-cell homeostasis and attenuates contact hypersensitivity response in mice. Allergy. 2015; 70(1):67-79

** Park, J; Schlederer, M; Schreiber, M; Ice, R; Merkel, O; Bilban, M; Hofbauer, S; Kim, S; Addison, J; Zou, J; Ji, C; Bunting, ST; Wang, Z; Shoham, M; Huang, G [and 10 others] (2015): AF1q is a novel TCF7 co-factor which activates CD44 and promotes breast cancer metastasis. Oncotarget. 2015; 6(24):20697-20710
Open Access Logo

** Pencik, J; Schlederer, M; Gruber, W; Unger, C; Walker, SM; Chalaris, A; Marié, IJ; Hassler, MR; Javaheri, T; Aksoy, O; Blayney, JK; Prutsch, N; Skucha, A; Herac, M; Krämer, OH [and 25 others] (2015): STAT3 regulated ARF expression suppresses prostate cancer metastasis. Nat Commun. 2015; 6:7736
Open Access Logo

** Pencik, J; Schlederer, M; Gruber, W; Unger, C; Walker, SM; Chalaris, A; Marié, IJ; Hassler, MR; Javaheri, T; Aksoy, O; Blayney, JK; Prutsch, N; Skucha, A; Herac, M; Krämer, OH [and 25 others] (2015): Erratum: STAT3 regulated ARF expression suppresses prostate cancer metastasis. Nat Commun. 2015; 6:8802
Open Access Logo

** Rupp, C; Scherzer, M; Rudisch, A; Unger, C; Haslinger, C; Schweifer, N; Artaker, M; Nivarthi, H; Moriggl, R; Hengstschläger, M; Kerjaschki, D; Sommergruber, W; Dolznig, H; Garin-Chesa, P (2015): IGFBP7, a novel tumor stroma marker, with growth-promoting effects in colon cancer through a paracrine tumor-stroma interaction. Oncogene. 2015; 34(7):815-825

** Schütz, A; Röser, K; Klitzsch, J; Lieder, F; Aberger, F; Gruber, W; Mueller, KM; Pupyshev, A; Moriggl, R; Friedrich, K (2015): Lung Adenocarcinomas and Lung Cancer Cell Lines Show Association of MMP-1 Expression With STAT3 Activation. Transl Oncol (8), 2 97-105.
Open Access Logo

** Weber, A; Borghouts, C; Brendel, C; Moriggl, R; Delis, N; Brill, B; Vafaizadeh, V; Groner, B (2015): Stat5 Exerts Distinct, Vital Functions in the Cytoplasm and Nucleus of Bcr-Abl+ K562 and Jak2(V617F)+ HEL Leukemia Cells. Cancers (Basel). 2015; 7(1):503-537

** Zhang, R; Gilbert, S; Yao, X; Vallance, J; Steinbrecher, K; Moriggl, R; Zhang, D; Eluri, M; Chen, H; Cao, H; Shroyer, N; Denson, L; Han, X (2015): Natural compound methyl protodioscin protects against intestinal inflammation through modulation of intestinal immune responses. Pharmacol Res Perspect. 2015; 3(2):e00118
Open Access Logo

Kongressbeitrag in einer Zeitschrift

** Maurer, B; Nivarthi, H; Prchal-Murphy, M; Wingelhofer, B; Chen, D; Winkler, S; Prochazkova, J; Schlederer, M; Pham, H; Loizou, JI; Kenner, L; Sexl, V; Kolbe, T; Kralovics, R; Müller, M [and 2 others] (2015): An activating STAT5 mutation is sufficient for Peripheral T Cell Lymphoma formation. 3rd Annual Meeting of the International-Cytokine-and-Interferon-Society (ICIS), Bamberg, GERMANY, Germany, OCT 11-14, 2015. Cytokine (76), 1 77-77.

** Pencik, J; Schlederer, M; Gruber, W; Unger, C; Walker, SM; Chalaris, A; Marie, I; Hassler, MR; Javaheri, T; Aksoy, O; Blayney, JK; Mazal, P; Grebien, F; Egger, G; Poli, V [and 19 others] (2015): Loss of IL-6/Stat3 signalling drives metastatic prostate cancer in mice and men. 3rd Annual Meeting of the International-Cytokine-and-Interferon-Society (ICIS), Bamberg, GERMANY, Germany, OCT 11-14, 2015. Cytokine (76), 1 112-112.

** Wingelhofer, B; Heyes, EC; Lewis, AM; Cumaraswamy, AA; Sadovnik, I; Valent, P; Kubicek, S; Gunning, PT; Moriggl, R (2015): Targeting STAT5 in Hematopoietic Malignancies. 3rd Annual Meeting of the International-Cytokine-and-Interferon-Society (ICIS), Bamberg, GERMANY, Germany, OCT 11-14, 2015. Cytokine (76), 1 77-77.

Publizierter (zitierfähiger) Beitrag für wissenschaftliche Veranstaltung in Proceedings (A2)

Moriggl, M; Javaheri, T (2015): Ewing sarcoma mouse development manifests in juveniles and requires Apoptosis escape and cell cycle progression. -Ewing Meeting; JUN 14-17, 2015; Paris, FRANCE.

Moriggl, R (2015): Illuminating STAT5 Biology in Cancers Through Gain or Loss of Function. -International Conference on Cytokine Signaling in Cancer; MAI 23-29, 2015; Kreta, Greece.

Moriggl, R (2015): GH-induced Jak2-Stat5 signalling and the influence by the glucocorticoid receptor pathway in liver cancer or metabolic diseases. -FASEB Meeting, Steamboat Springs, "The Growth Hormone/Prolactin Family in Biology and Disease"; JUL 11-19, 2015; Colarado, USA.

Moriggl, R (2015): Aberrant STAT5 gene dosage and hyperactivation status by cytokine or mutated tyrosine kinase signalling drives disease. -EMBO 8th Young Investigator Meeting in Warsaw; JUN 24-26, 2015; Warsaw, USA.

Morrigl, R (2015): Translational JAK-Stat phenotypes with implications for solid or hematopoietic cancer development. -LBI Annual Meeting – “From Translational Models to Targeted Therapy”; NOV 8-11, 2015; Vienna, Austria.

Pencik, J; Moriggl, R (2015): Aberrant STAT3-ARF signaling targets distinct subgroups of lethal prostate cancer. -12th Charles Rodolphe Brupbacher Symposium Breakthroughs in Cancer Research and Therapy; JAN 28-30, 2015; Zurich, Switzerland.

Pencik, J; Moriggl, R (2015): Loss of IL-6/Stat3 signalling drives metastatic prostate cancer in mice and men. -Third Annual Meeting of the International Cytokine & Interferon Society ; OKT 11-14, 2015; Bamberg, GERMANY.

2014

Zeitschriftenaufsatz

** Berger, A; Hoelbl-Kovacic, A; Bourgeais, J; Hoefling, L; Warsch, W; Grundschober, E; Uras, IZ; Menzl, I; Putz, EM; Hoermann, G; Schuster, C; Fajmann, S; Leitner, E; Kubicek, S; Moriggl, R [and 2 others] (2014): PAK-dependent STAT5 serine phosphorylation is required for BCR-ABL-induced leukemogenesis. Leukemia. 2014; 28(3):629-641
Open Access Logo

** Berger, A; Sexl, V; Valent, P; Moriggl, R (2014): Inhibition of STAT5: a therapeutic option in BCR-ABL1-driven leukemia. Oncotarget. 2014; 5(20):9564-9576
Open Access Logo

** Bibi, S; Arslanhan, MD; Langenfeld, F; Jeanningros, S; Cerny-Reiterer, S; Hadzijusufovic, E; Tchertanov, L; Moriggl, R; Valent, P; Arock, M (2014): Co-operating STAT5 and AKT signaling pathways in chronic myeloid leukemia and mastocytosis: possible new targets of therapy. Haematologica. 2014; 99(3):417-429
Open Access Logo

** Müller, S; Chen, Y; Ginter, T; Schäfer, C; Buchwald, M; Schmitz, LM; Klitzsch, J; Schütz, A; Haitel, A; Schmid, K; Moriggl, R; Kenner, L; Friedrich, K; Haan, C; Petersen, I [and 2 others] (2014): SIAH2 antagonizes TYK2-STAT3 signaling in lung carcinoma cells. Oncotarget. 2014; 5(10):3184-3196
Open Access Logo

** Rumi, E; Harutyunyan, AS; Casetti, I; Pietra, D; Nivarthi, H; Moriggl, R; Cleary, C; Bagienski, K; Astori, C; Bellini, M; Berg, T; Passamonti, F; Kralovics, R; Cazzola, M (2014): A novel germline JAK2 mutation in familial myeloproliferative neoplasms. Am J Hematol. 2014; 89(1):117-118

** Schlederer, M; Mueller, KM; Haybaeck, J; Heider, S; Huttary, N; Rosner, M; Hengstschläger, M; Moriggl, R; Dolznig, H; Kenner, L (2014): Reliable quantification of protein expression and cellular localization in histological sections. PLoS One. 2014; 9(7):e100822
Open Access Logo

** Strobl, B; Moriggl, R (2014): Recovery from chemotherapy depends on STAT1 for replenishment of B lymphopoiesis. J Leukoc Biol. 2014; 95(6):849-851

Publizierter (zitierfähiger) Beitrag für wissenschaftliche Veranstaltung in Proceedings (A2)

Berger, A; Hoelbl-Kovacic, A; Menzl, I; Kubicek, S; Moriggl, R; Gouilleux, F; Sexl, V (2014): Characterization of STAT5 serine phosphorylation as a drug target in BCR-ABL+ leukemia. -24. Vetpharm Symposium; SEP 11-12,2014; Zuerich, SWITZERLAND.

2013

Zeitschriftenaufsatz

** Chatain, N; Ziegler, P; Fahrenkamp, D; Jost, E; Moriggl, R; Schmitz-Van de Leur, H; Muller-Newen, G (2013): Src family kinases mediate cytoplasmic retention of activated STAT5 in BCR-ABL-positive cells. Oncogene. 2013; 32(31): 3587-3597.

** Gordziel, C; Bratsch, J; Moriggl, R; Knosel, T; Friedrich, K (2013): Both STAT1 and STAT3 are favourable prognostic determinants in colorectal carcinoma. Brit J Cancer. 2013; 109(1): 138-146.

** Kollmann, K; Heller, G; Schneckenleithner, C; Warsch, W; Scheicher, R; Ott, RG; Schäfer, M; Fajmann, S; Schlederer, M; Schiefer, AI; Reichart, U; Mayerhofer, M; Hoeller, C; Zöchbauer-Müller, S; Kerjaschki, D [and 9 others] (2013): A kinase-independent function of CDK6 links the cell cycle to tumor angiogenesis. Cancer Cell. 2013; 24(2):167-181
Open Access Logo

** McGuckin, CP; Jurga, M; Miller, AM; Sarnowska, A; Wiedner, M; Boyle, NT; Lynch, MA; Jablonska, A; Drela, K; Lukomska, B; Domanska-Janik, K; Kenner, L; Moriggl, R; Degoul, O; Perruisseau-Carrier, C; Forraz, N (2013): Ischemic brain injury: a consortium analysis of key factors involved in mesenchymal stem cell-mediated inflammatory reduction. Arch Biochem Biophys. 2013; 534(1-2):88-97

** Mueller, KM; Moriggl, R (2013): Reply: To PMID 21725989. Hepatology (58), 6 2210-2210.

** Sanda, T; Tyner, JW; Gutierrez, A; Ngo, VN; Glover, J; Chang, BH; Yost, A; Ma, W; Fleischman, AG; Zhou, W; Yang, Y; Kleppe, M; Ahn, Y; Tatarek, J; Kelliher, MA [and 10 others] (2013): TYK2-STAT1-BCL2 pathway dependence in T-cell acute lymphoblastic leukemia. Cancer Discov. 2013; 3(5):564-577
Open Access Logo

** Weber, A; Borghouts, C; Brendel, C; Moriggl, R; Delis, N; Brill, B; Vafaizadeh, V; Groner, B (2013): The inhibition of stat5 by a Peptide aptamer ligand specific for the DNA binding domain prevents target gene transactivation and the growth of breast and prostate tumor cells. Pharmaceuticals (Basel) (6), 8 960-987.

2012

** Friedbichler, K; Themanns, M; Mueller, KM; Schlederer, M; Kornfeld, JW; Terracciano, LM; Kozlov, AV; Haindl, S; Kenner, L; Kolbe, T; Mueller, M; Snibson, KJ; Heim, MH; Moriggl, R (2012): Growth-hormone-induced signal transducer and activator of transcription 5 signaling causes gigantism, inflammation, and premature death but protects mice from aggressive liver cancer. Hepatology. 2012; 55(3):941-952

** Gilbert, S; Zhang, R; Denson, L; Moriggl, R; Steinbrecher, K; Shroyer, N; Lin, J; Han, X (2012): Enterocyte STAT5 promotes mucosal wound healing via suppression of myosin light chain kinase-mediated loss of barrier function and inflammation. Embo Mol Med. 2012; 4(2):109-124

** Kovacic, B; Hoelbl, A; Litos, G; Alacakaptan, M; Schuster, C; Fischhuber, KM; Kerenyi, MA; Stengl, G; Moriggl, R; Sexl, V; Beug, H (2012): Diverging fates of cells of origin in acute and chronic leukaemia. EMBO Mol Med. 2012; 4(4):283-297
Open Access Logo

** Kovar, H; Alonso, J; Aman, P; Aryee, DN; Ban, J; Burchill, SA; Burdach, S; De Alava, E; Delattre, O; Dirksen, U; Fourtouna, A; Fulda, S; Helman, LJ; Herrero-Martin, D; Hogendoorn, PC [and 22 others] (2012): The first European interdisciplinary ewing sarcoma research summit. Front Oncol. 2012; 2:54
Open Access Logo

** Krämer, OH; Moriggl, R (2012): Acetylation and sumoylation control STAT5 activation antagonistically. JAKSTAT (1), 3 203-207.

** Laimer, D; Dolznig, H; Kollmann, K; Vesely, PW; Schlederer, M; Merkel, O; Schiefer, AI; Hassler, MR; Heider, S; Amenitsch, L; Thallinger, C; Staber, PB; Simonitsch-Klupp, I; Artaker, M; Lagger, S [and 23 others] (2012): PDGFR blockade is a rational and effective therapy for NPM-ALK-driven lymphomas. Nat Med. 2012; 18(11):1699-1704

** Mueller, KM; Themanns, M; Friedbichler, K; Kornfeld, JW; Esterbauer, H; Tuckermann, JP; Moriggl, R (2012): Hepatic growth hormone and glucocorticoid receptor signaling in body growth, steatosis and metabolic liver cancer development. Mol Cell Endocrinol. 2012; 361(1-2):1-11

** Musteanu, M; Blaas, L; Zenz, R; Svinka, J; Hoffmann, T; Grabner, B; Schramek, D; Kantner, HP; Müller, M; Kolbe, T; Rülicke, T; Moriggl, R; Kenner, L; Stoiber, D; Penninger, JM [and 3 others] (2012): A mouse model to identify cooperating signaling pathways in cancer. Nat Methods. 2012; 9(9):897-900

** Warsch, W; Grundschober, E; Berger, A; Gille, L; Cerny-Reiterer, S; Tigan, AS; Hoelbl-Kovacic, A; Valent, P; Moriggl, R; Sexl, V (2012): STAT5 triggers BCR-ABL1 mutation by mediating ROS production in chronic myeloid leukaemia. Oncotarget (3), 12 1669-1687.
Open Access Logo

2011

** Ermakova, O; Piszczek, L; Luciani, L; Cavalli, FM; Ferreira, T; Farley, D; Rizzo, S; Paolicelli, RC; Al-Banchaabouchi, M; Nerlov, C; Moriggl, R; Luscombe, NM; Gross, C (2011): Sensitized phenotypic screening identifies gene dosage sensitive region on chromosome 11 that predisposes to disease in mice. Embo Mol Med. 2011; 3(1):50-66

** Ferbeyre, G; Moriggl, R (2011): The role of Stat5 transcription factors as tumor suppressors or oncogenes. Bba-Rev Cancer. 2011; 1815(1): 104-114.

** Friedbichler, K; Hoelbl, A; Li, G; Bunting, KD; Sexl, V; Gouilleux, F; Moriggl, R (2011): Serine phosphorylation of the Stat5a C-terminus is a driving force for transformation. Front Biosci (Landmark Ed). 2011; 16:3043-3056

** Kornfeld, JW; Isaacs, A; Vitart, V; Pospisilik, JA; Meitinger, T; Gyllensten, U; Wilson, JF; Rudan, I; Campbell, H; Penninger, JM; Sexl, V; Moriggl, R; van Duijn, C; Pramstaller, PP; Hicks, AA (2011): Variants in STAT5B associate with serum TC and LDL-C levels. J Clin Endocrinol Metab. 2011; 96(9):E1496-E1501
Open Access Logo

** Leeb, C; Jurga, M; McGuckin, C; Forraz, N; Thallinger, C; Moriggl, R; Kenner, L (2011): New perspectives in stem cell research: beyond embryonic stem cells. Cell Proliferat. 2011; 44: 9-14.

** Mueller, KM; Kornfeld, JW; Friedbichler, K; Blaas, L; Egger, G; Esterbauer, H; Hasselblatt, P; Schlederer, M; Haindl, S; Wagner, KU; Engblom, D; Haemmerle, G; Kratky, D; Sexl, V; Kenner, L [and 8 others] (2011): Impairment of hepatic growth hormone and glucocorticoid receptor signaling causes steatosis and hepatocellular carcinoma in mice. Hepatology. 2011; 54(4):1398-1409
Open Access Logo

** Schneller, D; Machat, G; Sousek, A; Proell, V; van Zijl, F; Zulehner, G; Huber, H; Mair, M; Muellner, MK; Nijman, SM; Eferl, R; Moriggl, R; Mikulits, W (2011): p19(ARF) /p14(ARF) controls oncogenic functions of signal transducer and activator of transcription 3 in hepatocellular carcinoma. Hepatology. 2011; 54(1):164-172

** Warsch, W; Kollmann, K; Eckelhart, E; Fajmann, S; Cerny-Reiterer, S; Hölbl, A; Gleixner, KV; Dworzak, M; Mayerhofer, M; Hoermann, G; Herrmann, H; Sillaber, C; Egger, G; Valent, P; Moriggl, R; Sexl, V (2011): High STAT5 levels mediate imatinib resistance and indicate disease progression in chronic myeloid leukemia. Blood. 2011; 117(12):3409-3420
Open Access Logo

** Zugowski, C; Lieder, F; Müller, A; Gasch, J; Corvinus, FM; Moriggl, R; Friedrich, K (2011): STAT3 controls matrix metalloproteinase-1 expression in colon carcinoma cells by both direct and AP-1-mediated interaction with the MMP-1 promoter. Biol Chem. 2011; 392(5):449-459

2010

** Blaas, L; Kornfeld, JW; Schramek, D; Musteanu, M; Zollner, G; Gumhold, J; van Zijl, F; Schneller, D; Esterbauer, H; Egger, G; Mair, M; Kenner, L; Mikulits, W; Eferl, R; Moriggl, R [and 3 others] (2010): Disruption of the growth hormone--signal transducer and activator of transcription 5--insulinlike growth factor 1 axis severely aggravates liver fibrosis in a mouse model of cholestasis. Hepatology. 2010; 51(4):1319-1326

** Creamer, BA; Sakamoto, K; Schmidt, JW; Triplett, AA; Moriggl, R; Wagner, KU (2010): Stat5 promotes survival of mammary epithelial cells through transcriptional activation of a distinct promoter in Akt1. Mol Cell Biol. 2010; 30(12):2957-2970

** Friedbichler, K; Kerenyi, MA; Kovacic, B; Li, G; Hoelbl, A; Yahiaoui, S; Sexl, V; Müllner, EW; Fajmann, S; Cerny-Reiterer, S; Valent, P; Beug, H; Gouilleux, F; Bunting, KD; Moriggl, R (2010): Stat5a serine 725 and 779 phosphorylation is a prerequisite for hematopoietic transformation. Blood. 2010; 116(9):1548-1558
Open Access Logo

** Leeb, C; Jurga, M; McGuckin, C; Moriggl, R; Kenner, L (2010): Promising new sources for pluripotent stem cells. Stem Cell Rev Rep. 2010; 6(1):15-26

** Li, G; Miskimen, KL; Wang, Z; Xie, XY; Brenzovich, J; Ryan, JJ; Tse, W; Moriggl, R; Bunting, KD (2010): STAT5 requires the N-domain for suppression of miR15/16, induction of bcl-2, and survival signaling in myeloproliferative disease. Blood. 2010; 115(7):1416-1424

** Li, G; Miskimen, KL; Wang, Z; Xie, XY; Tse, W; Gouilleux, F; Moriggl, R; Bunting, KD (2010): Effective targeting of STAT5-mediated survival in myeloproliferative neoplasms using ABT-737 combined with rapamycin. Leukemia. 2010; 24(8):1397-1405

2009

** Baumgartner, C; Cerny-Reiterer, S; Sonneck, K; Mayerhofer, M; Gleixner, KV; Fritz, R; Kerenyi, M; Boudot, C; Gouilleux, F; Kornfeld, JW; Sillaber, C; Moriggl, R; Valent, P (2009): Expression of activated STAT5 in neoplastic mast cells in systemic mastocytosis: subcellular distribution and role of the transforming oncoprotein KIT D816V. Am J Pathol. 2009; 175(6):2416-2429

** Pflegerl, P; Vesely, P; Hantusch, B; Schlederer, M; Zenz, R; Janig, E; Steiner, G; Meixner, A; Petzelbauer, P; Wolf, P; Soleiman, A; Egger, G; Moriggl, R; Kishimoto, T; Wagner, EF; Kenner, L (2009): Epidermal loss of JunB leads to a SLE phenotype due to hyper IL-6 signaling. Proc Natl Acad Sci U S A. 2009; 106(48):20423-20428

** Schnidar, H; Eberl, M; Klingler, S; Mangelberger, D; Kasper, M; Hauser-Kronberger, C; Regl, G; Kroismayr, R; Moriggl, R; Sibilia, M; Aberger, F (2009): Epidermal growth factor receptor signaling synergizes with Hedgehog/GLI in oncogenic transformation via activation of the MEK/ERK/JUN pathway. Cancer Res. 2009; 69(4):1284-1292

2008

** Grebien, F; Kerenyi, MA; Kovacic, B; Kolbe, T; Becker, V; Dolznig, H; Pfeffer, K; Klingmüller, U; Müller, M; Beug, H; Müllner, EW; Moriggl, R (2008): Stat5 activation enables erythropoiesis in the absence of EpoR and Jak2. Blood. 2008; 111(9):4511-4522
Open Access Logo

** Harir, N; Boudot, C; Friedbichler, K; Sonneck, K; Kondo, R; Martin-Lannerée, S; Kenner, L; Kerenyi, M; Yahiaoui, S; Gouilleux-Gruart, V; Gondry, J; Bénit, L; Dusanter-Fourt, I; Lassoued, K; Valent, P [and 2 others] (2008): Oncogenic Kit controls neoplastic mast cell growth through a Stat5/PI3-kinase signaling cascade. Blood (112), 6 2463-2473.

Originalbeitrag in Sammelwerk

** Tsyrulnyk, A; Moriggl, R (2008): A detailed protocol for bacterial artificial chromosome recombineering to study essential genes in stem cells. IN: Bunting, KD [Hrsg.]: Hematopoietic Stem Cell Protocols (Methods in Molecular Biology, 430). Totowa, NJ, Humana, pp. 269-293. ISBN: 978-1-58829-868-3.

2007

Zeitschriftenaufsatz

** Engblom, D; Kornfeld, JW; Schwake, L; Tronche, F; Reimann, A; Beug, H; Hennighausen, L; Moriggl, R; Schütz, G (2007): Direct glucocorticoid receptor-Stat5 interaction in hepatocytes controls body size and maturation-related gene expression. Genes Dev (21), 10 1157-1162.

** Harir, N; Pecquet, C; Kerenyi, M; Sonneck, K; Kovacic, B; Nyga, R; Brevet, M; Dhennin, I; Gouilleux-Gruart, V; Beug, H; Valent, P; Lassoued, K; Moriggl, R; Gouilleux, F (2007): Constitutive activation of Stat5 promotes its cytoplasmic localization and association with PI3-kinase in myeloid leukemias. Blood. 2007; 109(4):1678-1686

** Li, G; Wang, Z; Zhang, Y; Kang, Z; Haviernikova, E; Cui, Y; Hennighausen, L; Moriggl, R; Wang, D; Tse, W; Bunting, KD (2007): STAT5 requires the N-domain to maintain hematopoietic stem cell repopulating function and appropriate lymphoid-myeloid lineage output. Exp Hematol. 2007; 35(11):1684-1694

** Tsareva, SA; Moriggl, R; Corvinus, FM; Wiederanders, B; Schütz, A; Kovacic, B; Friedrich, K (2007): Signal transducer and activator of transcription 3 activation promotes invasive growth of colon carcinomas through matrix metalloproteinase induction. Neoplasia. 2007; 9(4):279-291

** Tuckermann, JP; Kleiman, A; Moriggl, R; Spanbroek, R; Neumann, A; Illing, A; Clausen, BE; Stride, B; Förster, I; Habenicht, AJ; Reichardt, HM; Tronche, F; Schmid, W; Schütz, G (2007): Macrophages and neutrophils are the targets for immune suppression by glucocorticoids in contact allergy. J Clin Invest. 2007; 117(5):1381-1390

** Yao, Z; Kanno, Y; Kerenyi, M; Stephens, G; Durant, L; Watford, WT; Laurence, A; Robinson, GW; Shevach, EM; Moriggl, R; Hennighausen, L; Wu, C; O"Shea, JJ (2007): Nonredundant roles for Stat5a/b in directly regulating Foxp3. Blood. 2007; 109(10):4368-4375

2006

** Gatzka, M; Piekorz, R; Moriggl, R; Rawlings, J; Ihle, JN (2006): A role for STAT5A/B in protection of peripheral T-lymphocytes from postactivation apoptosis: insights from gene expression profiling. Cytokine. 2006; 34(3-4):143-154

** Jechlinger, M; Sommer, A; Moriggl, R; Seither, P; Kraut, N; Capodiecci, P; Donovan, M; Cordon-Cardo, C; Beug, H; Grünert, S (2006): Autocrine PDGFR signaling promotes mammary cancer metastasis. J Clin Invest. 2006; 116(6):1561-1570

2005

** Aichberger, KJ; Mayerhofer, M; Krauth, MT; Skvara, H; Florian, S; Sonneck, K; Akgul, C; Derdak, S; Pickl, WF; Wacheck, V; Selzer, E; Monia, BP; Moriggl, R; Valent, P; Sillaber, C (2005): Identification of mcl-1 as a BCR/ABL-dependent target in chronic myeloid leukemia (CML): evidence for cooperative antileukemic effects of imatinib and mcl-1 antisense oligonucleotides. Blood. 2005; 105(8):3303-3311

** Corvinus, FM; Orth, C; Moriggl, R; Tsareva, SA; Wagner, S; Pfitzner, EB; Baus, D; Kaufmann, R; Huber, LA; Zatloukal, K; Beug, H; Ohlschläger, P; Schütz, A; Halbhuber, KJ; Friedrich, K (2005): Persistent STAT3 activation in colon cancer is associated with enhanced cell proliferation and tumor growth. Neoplasia. 2005; 7(6):545-555

** Moriggl, R; Sexl, V; Kenner, L; Duntsch, C; Stangl, K; Gingras, S; Hoffmeyer, A; Bauer, A; Piekorz, R; Wang, D; Bunting, KD; Wagner, EF; Sonneck, K; Valent, P; Ihle, JN; Beug, H (2005): Stat5 tetramer formation is associated with leukemogenesis. Cancer Cell (7), 1 87-99.

2004

** Tronche, F; Opherk, C; Moriggl, R; Kellendonk, C; Reimann, A; Schwake, L; Reichardt, HM; Stangl, K; Gau, D; Hoeflich, A; Beug, H; Schmid, W; Schütz, G (2004): Glucocorticoid receptor function in hepatocytes is essential to promote postnatal body growth. Genes Dev (18), 5 492-497.

2003

** Szremska, AP; Kenner, L; Weisz, E; Ott, RG; Passegué, E; Artwohl, M; Freissmuth, M; Stoxreiter, R; Theussl, HC; Parzer, SB; Moriggl, R; Wagner, EF; Sexl, V (2003): JunB inhibits proliferation and transformation in B-lymphoid cells. Blood. 2003; 102(12):4159-4165

2002

** Bunting, KD; Bradley, HL; Hawley, TS; Moriggl, R; Sorrentino, BP; Ihle, JN (2002): Reduced lymphomyeloid repopulating activity from adult bone marrow and fetal liver of mice lacking expression of STAT5. Blood. 2002; 99(2):479-487

** Dolznig, H; Habermann, B; Stangl, K; Deiner, EM; Moriggl, R; Beug, H; Müllner, EW (2002): Apoptosis protection by the Epo target Bcl-X(L) allows factor-independent differentiation of primary erythroblasts. Curr Biol. 2002; 12(13):1076-1085

2001

** Hoffmeyer, A; Piekorz, R; Moriggl, R; Ihle, JN (2001): Gadd45gamma is dispensable for normal mouse development and T-cell proliferation. Mol Cell Biol. 2001; 21(9):3137-3143

2000

** Groner, B; Fritsche, M; Stöcklin, E; Berchtold, S; Merkle, C; Moriggl, R; Pfitzner, E (2000): Regulation of the trans-activation potential of STAT5 through its DNA-binding activity and interactions with heterologous transcription factors. Growth Horm Igf Res. 2000; 10 Suppl B:S15-S20

** Kieslinger, M; Woldman, I; Moriggl, R; Hofmann, J; Marine, JC; Ihle, JN; Beug, H; Decker, T (2000): Antiapoptotic activity of Stat5 required during terminal stages of myeloid differentiation. Genes Dev. 2000; 14(2):232-244

** Sexl, V; Piekorz, R; Moriggl, R; Rohrer, J; Brown, MP; Bunting, KD; Rothammer, K; Roussel, MF; Ihle, JN (2000): Stat5a/b contribute to interleukin 7-induced B-cell precursor expansion, but abl- and bcr/abl-induced transformation are independent of stat5. Blood. 2000; 96(6):2277-2283

** Sims, NA; Clément-Lacroix, P; Da Ponte, F; Bouali, Y; Binart, N; Moriggl, R; Goffin, V; Coschigano, K; Gaillard-Kelly, M; Kopchick, J; Baron, R; Kelly, PA (2000): Bone homeostasis in growth hormone receptor-null mice is restored by IGF-I but independent of Stat5. J Clin Invest. 2000; 106(9):1095-1103

** Wang, D; Moriggl, R; Stravopodis, D; Carpino, N; Marine, JC; Teglund, S; Feng, J; Ihle, JN (2000): A small amphipathic alpha-helical region is required for transcriptional activities and proteasome-dependent turnover of the tyrosine-phosphorylated Stat5. Embo J. 2000; 19(3):392-399

1999

** Erard, F; Garcia-Sanz, JA; Moriggl, R; Wild, MT (1999): Presence or absence of TGF-beta determines IL-4-induced generation of type 1 or type 2 CD8 T cell subsets. J Immunol. 1999; 162(1):209-214

** Friedrich, K; Kammer, W; Erhardt, I; Brändlein, S; Sebald, W; Moriggl, R (1999): Activation of STAT5 by IL-4 relies on Janus kinase function but not on receptor tyrosine phosphorylation, and can contribute to both cell proliferation and gene regulation. Int Immunol. 1999; 11(8):1283-1294

** Gingras, S; Moriggl, R; Groner, B; Simard, J (1999): Induction of 3beta-hydroxysteroid dehydrogenase/delta5-delta4 isomerase type 1 gene transcription in human breast cancer cell lines and in normal mammary epithelial cells by interleukin-4 and interleukin-13. Mol Endocrinol. 1999; 13(1):66-81

** Moriggl, R; Marine, JC; Topham, DJ; Teglund, S; Sexl, V; McKay, C; Piekorz, R; Wang, D; Parganas, E; Yoshimura, A; Ihle, JN (1999): Differential roles of cytokine signaling during T-cell development. Cold Spring Harb Symp Quant Biol. 1999; 64:389-395

** Moriggl, R; Sexl, V; Piekorz, R; Topham, D; Ihle, JN (1999): Stat5 activation is uniquely associated with cytokine signaling in peripheral T cells. Immunity. 1999; 11(2): 225-230.

** Moriggl, R; Topham, DJ; Teglund, S; Sexl, V; McKay, C; Wang, D; Hoffmeyer, A; van Deursen, J; Sangster, MY; Bunting, KD; Grosveld, GC; Ihle, JN (1999): Stat5 is required for IL-2-induced cell cycle progression of peripheral T cells. Immunity (10), 2 249-259.

1998

** Berchtold, S; Volarevic, S; Moriggl, R; Mercep, M; Groner, B (1998): Dominant negative variants of the SHP-2 tyrosine phosphatase inhibit prolactin activation of Jak2 (janus kinase 2) and induction of Stat5 (signal transducer and activator of transcription 5)-dependent transcription. Mol Endocrinol. 1998; 12(4):556-567

** Boucheron, C; Dumon, S; Santos, SC; Moriggl, R; Hennighausen, L; Gisselbrecht, S; Gouilleux, F (1998): A single amino acid in the DNA binding regions of STAT5A and STAT5B confers distinct DNA binding specificities. J Biol Chem. 1998; 273(51):33936-33941

** Lischke, A; Moriggl, R; Brändlein, S; Berchtold, S; Kammer, W; Sebald, W; Groner, B; Liu, X; Hennighausen, L; Friedrich, K (1998): The interleukin-4 receptor activates STAT5 by a mechanism that relies upon common gamma-chain. J Biol Chem. 1998; 273(47):31222-31229

** Moriggl, R; Erhardt, I; Kammer, W; Berchtold, S; Schnarr, B; Lischke, A; Groner, B; Friedrich, K (1998): Activation of STAT6 is not dependent on phosphotyrosine-mediated docking to the interleukin-4 receptor and can be blocked by dominant-negative mutants of both receptor subunits. Eur J Biochem. 1998; 251(1-2):25-35

** Moriggl, R; Kristofic, C; Kinzel, B; Volarevic, S; Groner, B; Brinkmann, V (1998): Activation of STAT proteins and cytokine genes in human Th1 and Th2 cells generated in the absence of IL-12 and IL-4. J Immunol. 1998; 160(7):3385-3392

1997

** Berchtold, S; Moriggl, R; Gouilleux, F; Silvennoinen, O; Beisenherz, C; Pfitzner, E; Wissler, M; Stöcklin, E; Groner, B (1997): Cytokine receptor-independent, constitutively active variants of STAT5. J Biol Chem. 1997; 272(48):30237-30243

** Moriggl, R; Berchtold, S; Friedrich, K; Standke, GJ; Kammer, W; Heim, M; Wissler, M; Stöcklin, E; Gouilleux, F; Groner, B (1997): Comparison of the transactivation domains of Stat5 and Stat6 in lymphoid cells and mammary epithelial cells. Mol Cell Biol. 1997; 17(7):3663-3678

** Stoecklin, E; Wissler, M; Moriggl, R; Groner, B (1997): Specific DNA binding of Stat5, but not of glucocorticoid receptor, is required for their functional cooperation in the regulation of gene transcription. Mol Cell Biol. 1997; 17(11):6708-6716

1996

** Kammer, W; Lischke, A; Moriggl, R; Groner, B; Ziemiecki, A; Gurniak, CB; Berg, LJ; Friedrich, K (1996): Homodimerization of interleukin-4 receptor alpha chain can induce intracellular signaling. J Biol Chem. 1996; 271(39):23634-23637

** Moriggl, R; Gouilleux-Gruart, V; Jähne, R; Berchtold, S; Gartmann, C; Liu, X; Hennighausen, L; Sotiropoulos, A; Groner, B; Gouilleux, F (1996): Deletion of the carboxyl-terminal transactivation domain of MGF-Stat5 results in sustained DNA binding and a dominant negative phenotype. Mol Cell Biol. 1996; 16(10):5691-5700

1995

** Gouilleux, F; Moritz, D; Humar, M; Moriggl, R; Berchtold, S; Groner, B (1995): Prolactin and interleukin-2 receptors in T lymphocytes signal through a MGF-STAT5-like transcription factor. Endocrinology. 1995; 136(12):5700-5708

© Veterinärmedizinische Universität Wien Hilfe und DownloadsErklärung zur Barrierefreiheit